CoChat

The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study

Open access

The DOI matches its Crossref record; 39 of the 41 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Available iron chelation regimes in thalassaemia may achieve different changes in cardiac and hepatic iron as assessed by MR. The aim of this study was to assess the efficacy of four available iron chelator regimes in 232 thalassaemia major patients by assessing the rate of change in repeated measurements of cardiac and hepatic MR. RESULTS: For the heart, deferiprone and the combination of deferiprone and deferoxamine significantly reduced cardiac iron at all levels of iron loading. As patients were on deferasirox for a shorter time, a second analysis ("Initial interval analysis") assessing the change between the first two recorded MR results for both cardiac and hepatic iron (minimum interval 12 months) was made. Combination therapy achieved the most rapid fall in cardiac iron load at all levels and deferiprone alone was significantly effective with moderate and mild iron load. In the liver, deferasirox effected significant falls in iron load and combination therapy resulted in the most rapid decline. CONCLUSION: With the knowledge of the efficacy of the different available regimes and the specific iron load in the heart and the liver, appropriate tailoring of chelation therapy should allow clearance of iron. Combination therapy is best in reducing both cardiac and hepatic iron, while monotherapy with deferiprone or deferasirox are effective in the heart and liver respectively. The outcomes of this study may be useful to physicians as to the chelation they should prescribe according to the levels of iron load found in the heart and liver by MR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1532-429x-11-20

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Rate of change of T2* according to severity of baseline cardiac iron load and chelation regime prescribed.
Figure 1 Rate of change of T2* according to severity of baseline cardiac iron load and chelation regime prescribed.CC BY · PubMed Central
Figure 2 Estimated annual rates of change of CIC and R2*. Estimated annual rates of change of CIC (r-CIC, mg/gdw per year) and R2* (sec-1) for each regime at starting T2* levels of 5, 11 and 17 ms (top panel) and quadratic fit curves respectively (bottom panel) as evaluated from the "repeated measurements analysis".
Figure 2 Estimated annual rates of change of CIC and R2*. Estimated annual rates of change of CIC (r-CIC, mg/gdw per year) and R2* (sec-1) for each regime at starting T2* levels of 5, 11 and 17 ms (top panel) and quadratic fit curves respectively (bottom panel) as evaluated from the "repeated measurements analysis".CC BY · PubMed Central
Figure 3 Annual rate of change of Estimated Cardiac Iron Concentration r-CIC comparing significance between the treatment regimes (Initial interval analysis). Significant comparisons (Mann Witney Test) • Overall: DFP -v- DFX p < 0.001, Comb -v- DFX p < 0.001 • Severe: Comb -v- DFX p = 0.04, DFX -v- DFO p = 0.07 (marginally non-significant) • Moderate: DFP -v- DFO p = 0.06, DFP -v- DFX p = 0.036, Comb -v- DFO p = 0.07, Comb -v- DFX p = 0.07 (both marginally non-significant) • Mild: No comparison was statistically significant.
Figure 3 Annual rate of change of Estimated Cardiac Iron Concentration r-CIC comparing significance between the treatment regimes (Initial interval analysis). Significant comparisons (Mann Witney Test) • Overall: DFP -v- DFX p < 0.001, Comb -v- DFX p < 0.001 • Severe: Comb -v- DFX p = 0.04, DFX -v- DFO p = 0.07 (marginally non-significant) • Moderate: DFP -v- DFO p = 0.06, DFP -v- DFX p = 0.036, Comb -v- DFO p = 0.07, Comb -v- DFX p = 0.07 (both marginally non-significant) • Mild: No comparison was statistically significant.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Research works printed but not linked: 3

  1. Eleftheriou, 2006, Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias; A subgroup analysis, Haematologica, 91, abst 999
  2. Pepe, 2008, Comparison of deferasirox, deferiprone and desferrioxamine effectiveness on myocardial iron concenrations and biventricular function by quantitative MRI in thalassemia major, ASH Annual Meeting, San Francisco, USA, 6–9 December
  3. Grady, 2000, Optimising chelation therapy: Combining deferiprone and deferoxamine, Blood, 96, 604

Cited by

See all 87

Metadata

Authors
Berdoukas, V., Chouliaras, G., Moraitis, P., Zannikos, K., Berdoussi, E., & Ladis, V.
Affiliations
National and Kapodistrian University of Athens (GR)
Corresponding author
Berdoukas, Vasilios
Venue
Journal of Cardiovascular Magnetic Resonance
Publisher
Elsevier BV
Published
2009-01
Volume
11
Issue
1
Pages
20
ISSN
1097-6647 (ISSN-L)
OpenAlex
W2107631387
Cited by
87
References
41
Citations by year
2026: 3 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 4 · 2017: 7 · 2016: 6 · 2015: 4 · 2014: 7 · 2013: 4 · 2012: 7
FWCI
4.75
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Cardiovascular Magnetic Resonance (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
Keywords
thalassemia major, iron chelation therapy, cardiac iron, hepatic iron, deferiprone, deferoxamine, deferasirox, iron overload, MRI iron quantification
MeSH terms
Deferiprone, Adult, Deferoxamine, Drug Therapy, Combination, Female, Humans, Iron, Iron Chelating Agents, Liver, Magnetic Resonance Imaging, Male, Myocardium, Pyridones, Retrospective Studies, Severity of Illness Index, Time Factors, Logistic Models, Treatment Outcome, beta-Thalassemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. https://app.cochat.ai/papers/10.1186/1532-429x-11-20
The paper
Berdoukas, V., Chouliaras, G., Moraitis, P., Zannikos, K., Berdoussi, E., & Ladis, V. (2009). The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. Journal of Cardiovascular Magnetic Resonance. https://doi.org/10.1186/1532-429x-11-20

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.